EUKYSTOL
Schizoaffective Disorder
Case Western Reserve UniversitySmall moleculePhase 4 / ApprovedDormant
BBB
72/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 66/ 100
- Competitive Position
- 81/ 100
Competitive context
30 Active assets in the Schizoaffective Disorder cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Paliperidone Luye Pharma Group Ltd. | Phase 4 | BBB |
Raloxifene Iris Sommer | Phase 4 | BBB |
QUETIAPINE Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 4 | BBB |
Risperidone Lyndra Inc. | Phase 4 | BBB |
Dexmedetomidine BioXcel Therapeutics Inc | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
EUKYSTOL is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →